Medical Device Marketing in India (MDR 2017 Aligned)

India's medical device market is estimated at ₹90,000 crore and among the top 20 globally. The market includes diagnostics equipment, surgical instruments, consumables, home-care devices, and the rapidly growing digital health device segment (wearables, home monitoring devices). India is also a significant manufacturing hub for medical devices under the PLI scheme.

Despite market size, medical device marketing in India is relatively underdeveloped compared to pharmaceutical marketing. Many device companies — domestic manufacturers in particular — underinvest in brand building, HCP education, and clinical evidence communication. This creates a clear competitive opportunity for device companies that build systematic marketing functions.

MDR 2017: The Regulatory Framework for Medical Device Marketing

The Medical Devices Rules, 2017 (MDR 2017) — notified under the Drugs and Cosmetics Act — govern the manufacture, import, sale, and distribution of medical devices in India. For marketing, the key MDR 2017 implications:

Classification: MDR 2017 classifies devices into Class A (low risk), B (low-moderate risk), C (moderate-high risk), and D (high risk). Marketing claims must align with the approved intended use — which is determined at the classification/registration stage.

Performance claims: A device can be marketed for its approved intended use only. A blood glucose monitor approved for self-monitoring of blood glucose cannot be marketed as a diabetes management system without a separate clinical claim registration.

EU MDR alignment: India's MDR 2017 was designed to progressively align with global standards, including EU MDR. For device companies seeking both Indian and export markets, aligning clinical evidence with EU MDR standards provides a dual benefit — supporting both Indian marketing claims and European regulatory submissions.

Surgeon and HCP-Targeted Communications

Medical devices — particularly surgical instruments, implants, and diagnostic equipment — are purchased by hospital procurement teams based on the recommendation of lead surgeons and department heads. The decision-maker is the clinician, not the patient.

ICG's HCP-targeted device marketing framework:

Clinical evidence communication: Surgeons evaluate devices on evidence. The marketing function for an innovative surgical device is, fundamentally, clinical evidence communication. ICG's Pharos Scribe produces device-specific evidence summaries, case series documentation, and clinical comparison papers — the content that builds surgeon conviction.

Conference programmes: Major surgical conferences — Indian Orthopaedic Association (IOA), Cardiology Society of India (CSI), Indian Association of Gastrointestinal Endosurgeons (IAGES), and specialty-specific equivalents — are the primary education and networking platforms where device adoption decisions are made. ICG designs conference programmes for device clients: symposia, hands-on workshops, clinical data presentations.

Hands-on training programmes: For surgical devices requiring technique adoption, hands-on training is both a marketing and an education function. ICG designs structured training programmes — cadaveric workshops, simulation lab sessions, proctoring programmes — that accelerate clinical adoption.

Post-Market Clinical Follow-Up (PMCF) as a Marketing Asset

EU MDR requires Post-Market Clinical Follow-Up (PMCF) for Class IIb and III devices — ongoing collection of clinical data after market launch. For device companies with genuine EU MDR-aligned PMCF programmes, the accumulating real-world evidence becomes a marketing asset.

ICG's approach: structure PMCF data collection not just for regulatory compliance but for clinical communication. Real-world outcome data — published as registry studies or case series in peer-reviewed journals — provides surgeon confidence that no pre-market study alone can generate.

Pharos Vigil supports PMCF data monitoring and signal detection. Pharos Scribe produces the publication manuscripts. This closed loop — from real-world evidence collection to peer-reviewed publication to HCP communication — is the medical device marketing function that compounds over time.

Home Care and Consumer Medical Devices

The consumer medical device segment — home blood pressure monitors, blood glucose meters, pulse oximeters, thermometers, CPAP devices, hearing aids — is marketed both to patients and through HCP recommendation.

Consumer device marketing considerations:

• DPDP compliance: Consumer health devices that collect data (connected glucometers, smart BP monitors) are data fiduciaries under the DPDP Act. Privacy architecture must be built before marketing is scaled.
• FSSAI/MDR classification: Wellness wearables that make health claims may trigger MDR classification. A step-counting watch is not an MDR device. A device claiming to detect atrial fibrillation is an MDR Class C or D device. The claim determines the classification.
• D2C + pharmacy channel hybrid: Consumer medical devices sell through both D2C (Amazon, brand website) and pharmacy retail. ICG's channel framework covers both — with different content and compliance considerations for each.

ICG's Medical Device Marketing Practice

ICG supports medical device companies across:

• Clinical evidence communication (Pharos Scribe)
• Conference programme design and execution
• Digital HCP engagement (email, HCP portals, LinkedIn)
• Consumer device D2C marketing (DPDP-compliant)
• International market entry marketing (EU + GCC + Southeast Asia)

Read next on ICG

• Pharma marketing agency India
• Pharos Scribe — clinical evidence writing
• Scientific writing services